THC, CBD, and CBN Activate a Key Drug Metabolism Receptor — Especially in Humans
All three major cannabinoids strongly activate the human pregnane X receptor at low concentrations, potentially altering how the body processes many common medications.
Quick Facts
What This Study Found
THC, CBD, and CBN activated human PXR at 10 μM by 28-fold, 23-fold, and 17-fold respectively — significantly more than rat or mouse PXR. The minimum effective concentration for human PXR was 0.3 μM, 10-33 times lower than for rodent PXR, suggesting species-specific drug interaction risks.
Key Numbers
Human PXR activation at 10 μM: THC 28-fold, CBD 23-fold, CBN 17-fold. Rat PXR: THC 9-fold, CBD 6-fold, CBN 4-fold. Mouse PXR: THC 4-fold, CBD 3-fold, CBN 3-fold. Human MEC: 0.3 μM (10-33x lower than rodent).
How They Did This
Concentration-response analysis using dual-luciferase reporter gene assays in human, rat, and mouse PXR-transfected HepG2 cells. Mammalian one-hybrid and two-hybrid assays confirmed ligand-binding domain transactivation and coactivator recruitment.
Why This Research Matters
PXR controls the expression of drug-metabolizing enzymes like CYP3A4, which processes about half of all prescription drugs. If cannabinoids activate this receptor at low concentrations, they could significantly alter how medications work in cannabis users.
The Bigger Picture
The dramatic species difference — human PXR is activated at much lower cannabinoid concentrations than rodent PXR — means animal studies may significantly underestimate the drug interaction potential of cannabinoids in humans.
What This Study Doesn't Tell Us
In vitro cell line study — actual in vivo PXR activation depends on cannabinoid concentrations reaching the liver. Transfected cell system may not fully replicate physiological conditions. Clinical drug interaction magnitude not measured.
Questions This Raises
- ?Do therapeutic cannabinoid doses achieve PXR-activating concentrations in the liver?
- ?Which specific drugs are most affected by cannabinoid-PXR-CYP3A4 interactions?
- ?Should cannabis users be screened for drug interactions?
Trust & Context
- Key Stat:
- Evidence Grade:
- Rigorous in vitro pharmacology with multiple assay systems, but clinical relevance depends on achieving these concentrations in vivo.
- Study Age:
- Published 2026, addressing growing need for cannabinoid drug interaction data.
- Original Title:
- Species differences in pregnane X receptor activation by Δ-9-tetrahydrocannabinol, cannabidiol, and cannabinol.
- Published In:
- Biochemical and biophysical research communications, 799, 153250 (2026)
- Authors:
- Lau, Aik Jiang, Chang, Thomas K H
- Database ID:
- RTHC-08413
Evidence Hierarchy
Frequently Asked Questions
Can cannabis affect how other medications work?
This study found that THC, CBD, and CBN all strongly activate a receptor (PXR) that controls how the body breaks down about half of all prescription drugs — suggesting cannabis could potentially speed up or alter the processing of many medications.
Why are animal studies misleading for cannabis drug interactions?
Human PXR is activated by cannabinoids at concentrations 10-33 times lower than rat or mouse PXR, meaning animal experiments may seriously underestimate how much cannabis affects drug metabolism in people.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- resin-vs-rosin-vs-live-rosin-difference
- what-is-live-rosin-why-expensive
- terpenes-explained-why-weed-smells-different
- entourage-effect-whole-plant-cannabis
- full-spectrum-vs-broad-spectrum-vs-isolate
Cite This Study
https://rethinkthc.com/research/RTHC-08413APA
Lau, Aik Jiang; Chang, Thomas K H. (2026). Species differences in pregnane X receptor activation by Δ-9-tetrahydrocannabinol, cannabidiol, and cannabinol.. Biochemical and biophysical research communications, 799, 153250. https://doi.org/10.1016/j.bbrc.2026.153250
MLA
Lau, Aik Jiang, et al. "Species differences in pregnane X receptor activation by Δ-9-tetrahydrocannabinol, cannabidiol, and cannabinol.." Biochemical and biophysical research communications, 2026. https://doi.org/10.1016/j.bbrc.2026.153250
RethinkTHC
RethinkTHC Research Database. "Species differences in pregnane X receptor activation by Δ-9..." RTHC-08413. Retrieved from https://rethinkthc.com/research/lau-2026-species-differences-in-pregnane
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.